NCT02711137 2025-10-21Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced MalignanciesIncyte CorporationPhase 1/2 Terminated137 enrolled 31 charts
NCT06662669 2024-10-29YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic CancerShanghai YingLi Pharmaceutical Co. Ltd.Phase 1/2 Not yet recruiting120 enrolled
NCT03649321 2023-11-09Clinical Trial of Chemotherapy and Bemcentinib for Metastatic Pancreatic CancerUniversity of Texas Southwestern Medical CenterPhase 1/2 Terminated9 enrolled 12 charts
NCT03989310 2020-12-23An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic CancerChinese PLA General HospitalPhase 1/2 Unknown50 enrolled
NCT02077881 2020-05-28Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic CancerLumos PharmaPhase 1/2 Completed157 enrolled